Chipscreen Biosciences, Ltd. is running a clinical trial to test a drug called Chiauranib to treat non-Hodgkin’s Lymphoma. Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin’s lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
The drug is Chiauranib.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 29 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin’s Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study |
| Actual Study Start Date : | May 9, 2017 |
| Estimated Primary Completion Date : | November 2018 |
| Estimated Study Completion Date : | May 2019 |
For enrollment please visit www.clinicaltrials.gov.
